USAMMDA’s WEMT PMO Visits Critical Innovations

This month, Critical Innovations was happy to host seven visitors from the U.S. Army Medical Materiel Development Activity’s (USAMMDA) Warfighter Expeditionary Medicine and Treatment (WEMT) PMO at the company’s Los Angeles facility. USAMMDA’s WEMT PMO leads the development and fielding of medical devices, drugs, and biologics that fulfill the unmet requirements identified by the military end-users. The site visit was led by Ms. Christine Parker, Project Manager of WEMT PMO.

The WEMT PMO reviewed the progress of devices being developed by Critical Innovations in three separate product areas:

• Burn Treatment and Skin Repair (BTSR)

• Noncompressible Hemorrhage Control (NHC)

• Temporary Corneal Repair (TCR)

“It was a pleasure hosting this team of DOD [Department of Defense] professionals and working with them towards the goal of developing innovative solutions to address catastrophic injuries for the Warfighter,” said Dr. Ross Donaldson, President & CEO of Critical Innovations. “We received very useful feedback and look forward to continued interactions with USAMMDA, as we together work to improve care for injured patients.”